发明名称 COMBINATION TREATMENT OF CANCER
摘要 <p>The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of these combinations may be useful in the treatment of cancer. The invention also relates to pharmaceutical compositions comprising such combinations, and further relates to methods of treatment comprising the simultaneous, sequential or separate administration of AZD5363, or a pharmaceutically acceptable salt thereof, with at least one androgen receptor signalling modulator as described above, to warm-blooded animal, such as a human for the treatment of cancer. The invention also relates to a kit comprising such combinations.</p>
申请公布号 WO2013079964(A1) 申请公布日期 2013.06.06
申请号 WO2012GB52969 申请日期 2012.11.30
申请人 ASTRAZENECA AB;ASTRAZENECA UK LIMITED 发明人 DAVIES, BARRY, ROBERT
分类号 A61K31/519;A61P13/08;A61P35/00 主分类号 A61K31/519
代理机构 代理人
主权项
地址